Name: Latest research reports of Aurobindo Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Value Stock, Under Radar

1161.1000 1.60 (0.14%)

NSE Jun 06, 2025 15:31 PM

27.07% Fall from 52W High

Volume: 392.6K

Aurobindo Pharma Ltd.

08 Aug 2019

1161.10

0.14%

Aurobindo Pharma (BUY): Good beat; progress on facility issues & Sandoz are key catalysts

Buy: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q1FY20 revenue/EBITDA beat estimates by 8%/10% spurred by strong US sales at US$ 384mn and 260bps gross margin expansion YoY and QoQ.

Aurobindo Pharma Ltd. is trading below all available SMAs